Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Investor's Business Daily on MSN1d
AstraZeneca Reverses As Beat And Raise Outweighs Drug Smuggling ClaimsAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.
More than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...
TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback